Novartis Ag

Donglei Liu

James J Powers

Nan Ji

Erik Meredith

Nello Mainolfi

Fupeng Ma

Chang Rao

Jason Matthew Elliott

Karl Miranda

Gerald David Artman, Iii

Stefan Peukert

Muneto Mogi

Christopher Michael Adams

Julien Papillon

Mitsunori Kato

Takeru Ehara

Atwood Kim Cheung

Yu Gai

Ganesh Prasanna

Luciana Ferrara

Doug Bevan

David B Belanger

Xingjuan Chang

Heng Ge

Gerald David Artman

Gerald David Artman Iii

The invention relates to a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein A, Rand Rare as described herein, as well as compositions and methods of using such compounds.

Naphthyridinone derivatives for the treatment of a disease or disorder

Provided herein are compounds and pharmaceutical compositions useful for treating diseases or disorders mediated by the TRPV1 receptor. The present invention also provides methods for treating ocular diseases or disorders by administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) or a pharmaceutical composition described herein.

1,3-substituted cyclobutyl derivatives and uses thereof

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Thiophen-2-yl-pyridin-2-yl-1H-pyrazole-4-carboxylic acid derivatives and the use thereof as soluble guanylate cyclase activators

The invention relates to novel organic compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula I and to the use of a compound of formula I for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in the treatment of tumour diseases and ocular neovascular diseases.

Heterobicyclic carboxamides as inhibitors for kinases

The invention relates to novel organic compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula I and to the use of a compound of formula I for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in the treatment of tumor diseases and ocular neovascular diseases.

Growing community of inventors

Cambridge, MA, United States of America

Donglei Liu